Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Improving the therapeutic index when using Myocet (TM) in the treatment ofmetastatic breast cancer
Autore:
Batist, G;
Indirizzi:
McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada McGill Univ Montreal PQ Canada H3T 1E2 Hosp, Montreal, PQ H3T 1E2, Canada
Titolo Testata:
BREAST
, volume: 10, anno: 2001, supplemento:, 2
pagine: 16 - 21
SICI:
0960-9776(200106)10:<16:ITTIWU>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
COMBINATION CHEMOTHERAPY; RANDOMIZED TRIAL; ONCOLOGY-GROUP; FOLLOW-UP; DOXORUBICIN; SURVIVAL; ADRIAMYCIN; CARDIOMYOPATHY; CARDIOTOXICITY; CARCINOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Batist, G McGill Univ, Jewish Gen Hosp, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada McGill Univ 3755 Cote St Catherine Montreal PQ Canada H3T 1E2 da
Citazione:
G. Batist, "Improving the therapeutic index when using Myocet (TM) in the treatment ofmetastatic breast cancer", BREAST, 10, 2001, pp. 16-21

Abstract

Improving the therapeutic index of anthracycline-based regimens in the management of metastatic breast cancer is a goal that physicians strive for inorder to improve quality of life and increase the small fraction of long-term disease-free survivors that have been observed in studies using anthracycline-based regimens. There are supporters and opponents of continuous anddose-intensive therapy for improving quality of life and providing a survival advantage, but the risk of cumulative toxicity associated with anthracycline-based regimens, especially, doxorubicin, is limiting in these approaches. Myocet (TM), has equivalent antitumour efficacy to doxorubicin, but significantly less cardiotoxicity. Consequently, the recommended cumulative lifetime dose of Myocet is 780 mg/m(2), compared with 450 mg/m(2) for doxorubicin. By using Myocet in the metastatic setting, and perhaps eventually inthe adjuvant treatment for primary breast cancer, an increased number of cycles can be given within the cardiotoxicity risk threshold, improving quality of life by delaying relapse. This improvement in therapeutic index may contribute to the fraction of long-term disease-free survivors and fulfils a previously unmet need in the overall management of breast cancer. (C) 2001 Harcourt Publishers Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 19:36:18